10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Lululemon Athletica Was Among The Worst-Performing Stocks Last Week (May 19-May 26, 2024): Are These 10 Large-Cap Stock Losers In Your Portfolio?
10 worst-performing large-cap stocks last week. National Grid, James Hardie, KE Holdings, JD.Com, XP, Nordson, BeiGene, Lululemon, Walgreens, and Li Auto.
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans’ Health Information Stolen In Data Breach In February
Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications.
Unveiling 4 Analyst Insights On Cencora
Throughout the last three months, 4 analysts have evaluated Cencora (NYSE:COR), offering a diverse set of opinions from…
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
US Federal Trade Commission Investigates Drug Shortages Amid Allegations Of Market Manipulation
FTC probes chemotherapy shortages, scrutinizing drug distributors and hospital groups. Root causes of drug shortages under scrutiny. Industry defends practices.
Walgreens Boots Sells Cencora Shares For $992M, Decreases Ownership To ~13%; Cencora Repurchases $50M
Walgreens Boots Alliance announces sale of shares of Cencora, Inc. for proceeds of $992 million
Approximately $942 million sold pursuant to Rule 144 along with a concurrent share repurchase by Cencora
Wednesday Is Your Last Chance To Buy Cencora Before The Dividend Payout
Wednesday marks the last chance for investors to receive the next dividend payout from Cencora (NYSE:COR). What’s Happening…
Peering Into Cencora’s Recent Short Interest
Cencora’s (NYSE:COR) short percent of float has risen 8.1% since its last report. The company recently reported that…
Drug Wholesale Firm Cencora Starts 2024 With Strong Growth, Lifts Annual Forecast On Commercial COVID-19 Vaccine Distribution
Cencora reports Q1 2024 results with adjusted EPS at $3.28 and revenue of $72.3 billion. Explore the company's fiscal year 2024 guidance and growth projections.